| Original language | English (US) |
|---|---|
| Pages (from-to) | 961-966 |
| Number of pages | 6 |
| Journal | British Journal of Haematology |
| Volume | 185 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jun 2019 |
Keywords
- B-cell receptor signalling pathway inhibitor
- chronic lymphocytic leukaemia
- refractory
- relapsed
- venetoclax
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: British Journal of Haematology, Vol. 185, No. 5, 06.2019, p. 961-966.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor
AU - Wierda, William G.
AU - Byrd, John C.
AU - Davids, Matthew S.
AU - Furman, Richard R.
AU - Cheson, Bruce D.
AU - Barr, Paul M.
AU - Eradat, Herbert
AU - Heffner, Leonard
AU - Zhou, Lang
AU - Verdugo, Maria
AU - Potluri, Jalaja
AU - Choi, Michael
N1 - Funding Information: W Wierda: Research funding from AbbVie, Genentech. J Byrd: Clinical trial support from Pharmacyclics and Acerta; Unpaid consultant for Genentech, AbbVie, Acerta, Pharma-cyclics, Leukemia and Lymphoma Society LLC. M Davids: Advisory board member for Genentech, Pharmacyclics, TG Therapeutics, Gilead, Incyte; Institutional research funding from Genentech, Pharmacyclics, TG Therapeutics, BMS, MEI Pharma, Surface Oncology; Consultant for Genentech, Abb-Vie, Pharmacyclics, Janssen, Merck, Celgene, Astra-Zeneca. R Furman: Consultant for AbbVie, Pharmacyclics, Janssen, Gilead, Genentech, Sunesis, Verastem, TG Therapeutics. B Cheson: Paid consultancy for AbbVie, Roche-Genentech, Pharmacyclics, Acerta; Institution receives research support from Acerta, Pharmacyclics, Roche, AbbVie, TG Therapeutics. P Barr: Consultancy for AbbVie, Gilead, Verastem, Cel-gene. H Eradat: Consultant for AbbVie, Gilead, Genentech; Advisory board member for AbbVie, Gilead, Genentech; Speaker for AbbVie, Gilead, Genentech. L Heffner: Institutional Research funding from Abbvie and Pharmacyclics. L Zhou, M Verdugo, J Potluri: AbbVie employees and own stock. M Choi: Advisory board/consultancy for AbbVie and PCYC; Institutional research funding from Pharmacyclics and AbbVie; Speakers bureau for Gilead, Genentech, Abbvie, and Pharmacyclics.
PY - 2019/6
Y1 - 2019/6
KW - B-cell receptor signalling pathway inhibitor
KW - chronic lymphocytic leukaemia
KW - refractory
KW - relapsed
KW - venetoclax
UR - http://www.scopus.com/inward/record.url?scp=85057283456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057283456&partnerID=8YFLogxK
U2 - 10.1111/bjh.15666
DO - 10.1111/bjh.15666
M3 - Letter
C2 - 30478940
AN - SCOPUS:85057283456
SN - 0007-1048
VL - 185
SP - 961
EP - 966
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -